Zev Biotech and the development of genomics platforms

This startup, that arise in Bioloop (UNSAM), has the mission of produce and commercialize molecular diagnostic kits for clinical laboratories, hospitals and health centers, both public and private, of emerging countries.

Zev Biotech is a science -based company that, in 2014, arise from the combination of  knowledge in molecular biology of its founder, Maximiliano Irisarri – biochemist and Doctor in Biological Sciences – and a specific problem of our country and  emerging countries in general:  the incompatibility of imported diagnosis equipment and the specific needs of our clinical laboratories.

 

In recent years, since the development of biochemical methods and techniques, which allow to determinate the complete human DNA sequence – heritable genetic information – molecular diagnosis became a reality, which in turn made it possible to predict, diagnose and/or assess the treatment of diseases with a greater degree of certainty, faster and in a personalized way.

 

In the market there are different genomics platforms for molecular diagnostic developed in advanced countries  that does not corresponding with the needs of local laboratories for various reasons: the requirement of a high level of investment in equipment and inputs,  the mandatory requirement of  process a large volume of samples in centralized health centers which, in many cases, also need certain building conditions and highly qualified staff to move forward with the diagnosis.

Zev Biotech developed a platform, called IRIS, intended to meet the needs of our health system and the healthcare system of comparable countries: that might be easy to deploy

Dr. Andres Barcala – ZEV Biotech

In view of this difficulty, Zev Biotech developed a platform, called IRIS, intended to meet the needs of our health system and the healthcare system of comparable countries: that might be easy to apply – supplementary equipment for its use, which are usually found in any molecular biology laboratory -, using cheaper inputs and offering the possibility to work with a smaller number of samples  and in a more versatile form, because allows to analyze different pathologies at the same time.

Today, the company is in product approval process by the National Drugs, Food and Medical Technology Administration (ANMAT) – which they aspire to reach in the coming months – and after, it will be time to go to market  and to assess the developing receptivity: “Ours clients are clinical analysis laboratories and any health care center which carry out diagnosis,  whether public or private.

Our aim is to supply laboratories with the equipment and kits they need to provide molecular diagnostic testing services”, says Andrés Barcala, member of Zev.

Finally, on the recent incubation in the Richard Feynman’s Space (FAN), Dr. Barcala concluded: “By a space and growth need, staying here is one step forward; having our own facilities is a big advantage.

We have encountered startups as neighbors, and we receive visits of institutions or individuals related with the entrepreneurial ecosystem, and this opens to us a great number of opportunities.

 

A partner, client or collaborator could arise from a commentary, contact or interest. In this stage of Zev, we have many benefits for be in FAN”.